**Supplementary Material 2**

**Figure S1.** Performance of objective response rate (ORR) and (DCR) as surrogate endpoint for overall survival (OS) in immuno-oncology trials of advanced gastro-esophageal carcinoma.



Correlation between ORR (A) and DCR (B) and OS at arm-level. Each dot represents one of the experimental arms of the phase 3 clinical trials, with size of the dot being proportional to the sample size. Correlation treatment effects on ORR (C) and DCR (D) and OS at trial-level. Size of dots is proportional to weighted sample size. The blue line represents the upper and lower 95% confidence intervals of the regression line (red line). Trials are colored based on whether the endpoint results were statistically significant.

*Abbreviations: Nivo, nivolumab; Pembrolizumab, Pembro; Ipi, ipilimumab; C, chemotherapy; GC, gastric carcinoma; ESCA, esophageal carcinoma; OR, odds ratio; HR, hazard ratio; ORR, objective response rate; DCR, disease control rate; OS, overall survival; NS, not significant; R, weighted Pearson correlation coefficient.*